A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

M. H. Langenberg, L. Gluck, V. Weger, R. Frank, F. Eskens, J. Y. Blay, J. C. Soria, S. Chawla, M. Gounder, A. Wagner, Y. Zhang, P. Kambuj, R. Loberg, H. Henary

Research output: Contribution to journalMeeting AbstractOther research output

Original languageEnglish
Pages (from-to)S34-S34
JournalEuropean Journal of Cancer
Issue numberSuppl. 1
Publication statusPublished - Dec 2016

Cite this